Have a feature idea you'd love to see implemented? Let us know!

PDSB PDS Biotechnology Corp

Price (delayed)

$3.315

Market cap

$122.06M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.23

Enterprise value

$88.7M

PDS Biotech is a clinical-stage immunotherapy company with a growing pipeline of cancer immunotherapies and infectious disease vaccines based on the Company's proprietary Versamune® T-cell activating technology platform. Versamune® effectively ...

Highlights
PDS Biotechnology's EPS has increased by 24% YoY and by 10% QoQ
PDS Biotechnology's net income has increased by 15% YoY and by 7% from the previous quarter
The quick ratio has plunged by 52% YoY and by 17% from the previous quarter
The equity has contracted by 17% from the previous quarter and by 4.7% YoY

Key stats

What are the main financial stats of PDSB
Market
Shares outstanding
36.82M
Market cap
$122.06M
Enterprise value
$88.7M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.93
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$39.71M
EBITDA
-$39.65M
Free cash flow
-$34.43M
Per share
EPS
-$1.23
Free cash flow per share
-$0.94
Book value per share
$0.84
Revenue per share
$0
TBVPS
$1.65
Balance sheet
Total assets
$60.5M
Total liabilities
$29.58M
Debt
$24.38M
Equity
$30.92M
Working capital
$44.49M
Liquidity
Debt to equity
0.79
Current ratio
3.84
Quick ratio
3.68
Net debt/EBITDA
0.84
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-66.1%
Return on equity
-137.1%
Return on invested capital
-297.9%
Return on capital employed
-88.6%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

PDSB stock price

How has the PDS Biotechnology stock price performed over time
Intraday
2.95%
1 week
6.42%
1 month
-13.22%
1 year
-21.07%
YTD
-33.3%
QTD
-13.22%

Financial performance

How have PDS Biotechnology's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$39.71M
Net income
-$40.68M
Gross margin
N/A
Net margin
N/A
The operating income has grown by 18% YoY and by 9% from the previous quarter
PDS Biotechnology's net income has increased by 15% YoY and by 7% from the previous quarter

Growth

What is PDS Biotechnology's growth rate over time

Valuation

What is PDS Biotechnology stock price valuation
P/E
N/A
P/B
3.93
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
PDS Biotechnology's EPS has increased by 24% YoY and by 10% QoQ
The P/B is 22% lower than the last 4 quarters average of 4.9 but 6% higher than the 5-year quarterly average of 3.6
The equity has contracted by 17% from the previous quarter and by 4.7% YoY

Efficiency

How efficient is PDS Biotechnology business performance
PDS Biotechnology's ROIC has decreased by 24% YoY and by 3.2% from the previous quarter
PDSB's ROE is down by 18% YoY but it is up by 6% QoQ
The ROA is up by 6% QoQ

Dividends

What is PDSB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for PDSB.

Financial health

How did PDS Biotechnology financials performed over time
PDS Biotechnology's total assets is 105% more than its total liabilities
PDSB's current ratio has dropped by 52% year-on-year and by 16% since the previous quarter
The quick ratio has plunged by 52% YoY and by 17% from the previous quarter
PDS Biotechnology's debt is 21% lower than its equity
The debt to equity is up by 22% since the previous quarter and by 10% year-on-year
The equity has contracted by 17% from the previous quarter and by 4.7% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.